Adaptin Bio (APTN) Cash from Operations Growth (1y) (2024 - 2026)
Powered by 
Analysis
Adaptin Bio (APTN) Cash from Operations Growth (1y) (2024 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 41.84% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 9.83% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -58.33% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -24.59% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 97.11% |
| 10 | Adaptin Bio | 56.76 Mn | 56.09 Mn | - | 55.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 55.98% |
| Mar 31, 2026 | 73.85% |
| Dec 31, 2025 | -723.93% |
| Sep 30, 2025 | -64.90% |
| Jun 30, 2025 | -401.76% |
| Mar 31, 2025 | -2,441.81% |
| Dec 31, 2024 | 293.07% |